Aberdeen Group plc raised its stake in Vericel Corporation (NASDAQ: VCEL) by 204.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,164,250 shares of the biotechnology company's stock after purchasing an additional 1,454,012 shares during the period. Aberdeen
BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026.
Vericel Corporation (VCEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Vericel NASDAQ: VCEL raised its full-year revenue and profitability outlook after third-quarter sales rose 26%, led by growth in its MACI cartilage repair product and a record quarter for its burn care business.
Vericel Corporation ( VCEL ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Samuil-Hrabar Gatev - Leerink Partners LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2026 Earnings Call.
Vericel Corporation (NASDAQ: VCEL - Get Free Report)'s stock price hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $54.49 and last traded at $55.2960, with a volume of 170,887 shares trading hands. The stock had previously closed at $45.48. The
Vericel Corporation (VCEL) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.1 per share a year ago.
Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% to $14.2 Million Adjusted EBITDA Margin of 30% Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28% Conference Call Today at 8:30am Eastern Time
Vericel (NASDAQ: VCEL - Get Free Report) and Alkermes (NASDAQ: ALKS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Analyst Recommendations This is a summary of recent ratings
Zymeworks (NASDAQ: ZYME - Get Free Report) and Vericel (NASDAQ: VCEL - Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Earnings and Valuation This table compares Zymeworks and Vericel"s